CryoPort (NASDAQ:CYRX) CEO Jerrell Shelton Sells 28,800 Shares

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the sale, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CryoPort Trading Up 0.9%

Shares of CYRX stock traded up $0.13 during trading hours on Tuesday, reaching $14.95. The company’s stock had a trading volume of 624,658 shares, compared to its average volume of 591,327. CryoPort, Inc. has a one year low of $7.61 and a one year high of $16.89. The stock has a market capitalization of $757.20 million, a P/E ratio of -16.61 and a beta of 1.89. The firm’s fifty day simple moving average is $15.47 and its 200 day simple moving average is $11.95.

CryoPort (NASDAQ:CYRX) last announced its earnings results on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. As a group, equities research analysts forecast that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CryoPort

Several hedge funds have recently made changes to their positions in CYRX. Basepoint Wealth LLC purchased a new stake in CryoPort in the fourth quarter worth $34,000. Tower Research Capital LLC TRC lifted its position in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after buying an additional 4,375 shares during the period. Quadrature Capital Ltd purchased a new position in CryoPort during the fourth quarter valued at $97,000. Corient Private Wealth LLC purchased a new position in CryoPort during the fourth quarter valued at $113,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock valued at $113,000 after buying an additional 4,225 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on CYRX shares. Needham & Company LLC upped their price objective on shares of CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CryoPort in a research note on Monday, August 3rd. KeyCorp lifted their target price on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Guggenheim boosted their price target on shares of CryoPort from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. Finally, Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.